John Linnan has been appointed vice president of sales at Agencourt Bioscience, the Beverly, Mass. company said last week.
Linnan comes to Agencourt from Applied Biosystems, where he most recently worked as district sales manager for New England. Previously, Linnan was the regional sales manager for New England, mid-Atlantic, and Eastern Canada for Perspective Biosystems of Hertford, UK. He has also worked at Abbott Diagnostics in various sales positions. He has a BA in marketing and management from James Madison University.
Andrew DePristo has been named president and CEO of Bioreason, of Santa Fe, NM, the company said last week. DePristo comes to the drug discovery informatics company from Amgen, where he was senior director of research and preclinical development information systems. He was also founding president of GeneData’s US subsidiary, and also served as vice president of bioinformatics, information technology, and emerging technology at Genome Therapeutics. DePristo received a PhD in theoretical chemistry from the University of Maryland.
Agilent Technologies has named
as vice president and general manager of the consumables and services business in its Life Sciences and Chemical Analysis group, the company said last week. Van, who joined Hewlett-Packard in 1997, and remained with Agilent when it spun out from its parent in 1999, is being promoted from a position as controller of the consumables and services business. Prior to joining the company, Van was director of finance and administration at Integrated Circuit Systems. Van holds a BS in accounting from Texas Tech University, and an MBA from West Chester University in Pennsylvania.
Benitec has named two additional members to its scientific advisory board: David Engelke is director of the University of Michigan program in biomedical sciences, and is also professor of biological chemistry. He is an expert on small RNAs, including those that induce RNA interference, the company said. Cy Stein is head of medical genitourinary oncology and professor of medicine, urology and molecular pharmacology at the Albert Einstein College of Medicine in New York. For the past 15 years, he has been involved with nucleic acid therapy for cancer, and of late, has focused on RNA interference in this area. Both professors will assist the SAB, which is headed by John Rossi of the City of Hope National Medical Center to provide guidance to Benitec in meeting its goal of developing therapeutics using its DNA-directed RNA interference technology, the company said.
Karen Moore has been named chief science officer of BioPoint Solutions, the biopharma data management company said last week. Moore was previously a consultant at UK-based Etiologics, and facilitated the company’s expansion to the US, BioPoint said. She was a co-founder of Hypnion, a sleep disorder therapeutics firm, and previously held management-level positions with Millennium Pharmaceuticals, which she joined at its founding in 1993.
Stuart Kim of Stanford University has won the Ho-Am Prize in medicine for his work on Caenorhabditis elegans developmental genetics, the University said last week.